HPN424

HPN424 · Harpoon Therapeutics, Inc. (subsidiary of Merck & Co., Inc.)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HPN424, covering 2024-02-14 to 2024-02-14. Get the full timeline:

Most recent: Clinical Trial Update: Study of HPN424 in Patients With Advanced Prostate Cancer [Phase 1, Phase 2]